PRMT5 and cancer: MRTX9768, a compound developed by Miratis Therapeutics, Inc., is focused on inhibiting the methylthioadenosine phosphorylase (MTA)-PRMT5 complex in MTAPdel cancer cells, resulting in their targeting for destruction [94].